Methods of increasing T cell immune response in the treatment of cancer
US10934354B2 · kind B2 · utility
0Cited by
16References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 30, 2018 |
| Grant date | Mar 2, 2021 |
| Priority date | — |
| Expiry date | Mar 30, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.